openFDA
Cure8 regulatory brief
Sulfasalazine FDA label update (2026-07-27)
Medications
Sulfasalazine
Aminosalicylates
Regulatory Update
Adult patients
Clinicians
Patients On Biologics
Ulcerative colitis
Why This Matters
This DailyMed entry is an official FDA drug-label record describing indications, dosing, and safety information for sulfasalazine—an older prescription medication still used in ulcerative colitis. Updated label details affect how clinicians prescribe and counsel patients on risks and monitoring.
Who Should Pay Attention
Adults with ulcerative colitis, caregivers of pediatric patients using sulfasalazine, prescribing clinicians, and pharmacists.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This is an FDA DailyMed label update for sulfasalazine, a prescription drug indicated for treatment and maintenance of ulcerative colitis.
The label describes approved adult and pediatric dosing, guidance on initiating and adjusting doses, evaluation of response (including clinical criteria and endoscopy), and recommendations for managing gastrointestinal intolerance and desensitization protocols in certain sensitive patients.
The label lists common adverse reactions (anorexia, headache, nausea, vomiting, gastric distress, reversible oligospermia) and a long section of less common and rare but serious adverse reactions affecting blood, liver, lungs, skin, nervous system, kidneys, and other organ systems.
It also notes that higher daily doses (≥4 g) or elevated serum sulfapyridine levels are associated with increased adverse reactions and mentions postmarketing reports.
If you take sulfasalazine or care for someone who does, the label information covers how dosing is adjusted, what side effects to watch for, and that some reactions can be severe; it does not provide personalized medical advice. For changes to treatment or questions about side effects, contact your prescribing clinician.
Keep In Mind
This is a regulatory drug label (DailyMed) reflecting approved indications, dosing guidance, and safety information. It summarizes known risks including rare but serious adverse events and postmarketing reports; it is not a clinical guideline or new clinical study result.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorAmerican Health Packaging
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 27, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
mesalamine FDA label update (2026-07-14)
This label update lists safety concerns that affect people taking mesalamine for ulcerative colitis, including the need for kidney monitoring, signs of hypersensitivity, and rare but serious skin and liver reactions.
Impact of 5-aminosalicylic acid intolerance on progression to difficult-to-treat ulcerative colitis: a retrospective cohort study.
If you have ulcerative colitis and cannot tolerate 5-ASA (mesalamine), this study suggests you may be at higher risk of progressing to difficult-to-treat disease, particularly if your intolerance fits an acute...
Rescue Vedolizumab Therapy for a Rare Case of Complicated Severe Ulcerative Colitis: A Case Report and Literature Review.
This case report describes successful use of vedolizumab to treat severe UC in a patient who also had PSC and SLE — a rare and complex combination. Patients and clinicians may find it relevant when considering biologic...